Dr Tom Lumbers is an honorary consultant cardiologist at University College London Hospitals (UCLH) and Barts Heart Centre, UKRI Rutherford fellow at University College London, and visiting scientist at the Broad Institute of Harvard and MIT.
After graduating in medicine from Cambridge University with double distinction he went on trained in clinical cardiology at UCLH and Barts Heart Centre. Alongside his clinical work, he received a PhD in molecular biology from Imperial College London and subsequently completed post-doctoral training in genetic epidemiology at University College London, as an NIHR clinical lecturer in cardiology.
Tom’s clinical work is based at UCLH and the Barts Heart Centre with interests in general cardiology, heart failure and clinical genetics. He leads the inpatient heart failure service at UCLH and is a member of the NIH ClinGen Dilated Cardiomyopathy Expert Group.
He co-leads the genomics group at the Institute of Health Informatics and his research focuses on defining the genetic basis of heart failure to generate insights into disease mechanisms to improve diagnosis and treatment.
Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Rafik Tadros*, Catherine Francis*, Xiao Xu*, Alexa MC Vermeer*, …, R Thomas Lumbers, …, Hugh Watkins*, Paul M Matthews*, James S Ware*, Connie R Bezzina*. Nature Genetics 2020 in press
Estimating the effect of reduced attendance at emergency departments for suspected acute cardiovascular disease on cardiovascular mortality during the COVID-19 pandemic. Michail Katsoulis, Manuel Gomes, …, Harry Hemingway, R Thomas Lumbers. Circulation: Cardiovascular Quality and Outcomes 2020
Body mass index and heart failure: a cohort study in 1.5 million individuals and Mendelian randomisation analysis. R. Thomas Lumbers*, Michail Katsoulis*, Albert Henry, Ify Mordi, Chim Lang, Harry Hemingway, Claudia Langenberg, Michael Holmes, Naveed Sattar, on behalf of the HERMES Consortium. BioRxiv 2020 https://doi.org/10.1101/2020.09.23.20200360
A genetic model of ivabradine treatment recapitulates challenging results from randomized clinical trials. Marc-André Legault, …, R Thomas Lumbers, Simon de Denus B. Pharm. Ph.D., Jean-Claude Tardif M.D., Marie-Pierre Dubé Ph.D. PLOS One 2020. doi: 10.1101/2020.01.29.20019521.
Genome-wide association study provides new insights into the genetic architecture and pathogenesis of heart failure. Sonia Shah*, Albert Henry*, >150 co-authors, Lumbers RT Nature Communications 2020. doi: 10.1038/s41467-019-13690-5
Do beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve outcomes in patients with heart failure and left ventricular ejection fraction greater than 40 percent? R. Thomas Lumbers, Nicole Martin, Karthick Manoharan, James Thomas, Ceri Davies. Heart, July 2019. doi:10.1136/heartjnl-2018-313855
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. N. Martin, K. Manoharan, J. Thomas, C. Davies, RT Lumbers. Cochrane Database of Systematic Reviews 2018.